<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001872</url>
  </required_header>
  <id_info>
    <org_study_id>990037</org_study_id>
    <secondary_id>99-H-0037</secondary_id>
    <nct_id>NCT00001872</nct_id>
  </id_info>
  <brief_title>Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease</brief_title>
  <official_title>Apheresis of Family Members of Patients Undergoing Allogeneic Bone Marrow Transplantation. A Pre-Clinical Study of Selective Depletion of Donor Lymphocytes to Prevent Acute Graft-Versus-Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Blood contains different kinds of cells, white blood cells, red blood cells, and platelets.
      In order to treat certain diseases, specific cell types can be removed from blood and
      transplanted into patients. The process of removing white blood cells for the treatment of
      leukemia is called apheresis.

      This study will make available blood cell collections from volunteers genetically matched to
      various degrees with recipients in order to test and, if necessary, refine the process of
      removing white blood cell T-lymphocytes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol has been written to make available apheresis collections from volunteers
      matched to various degrees with recipients in order to test and, if necessary refine, the
      selective immunodepletion procedure prior to introducing it in a clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2, 1999</start_date>
  <completion_date>March 2, 2018</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">14</enrollment>
  <condition>Graft vs Host Disease</condition>
  <condition>Hematologic Neoplasm</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Family members of patients admitted to NHLBI allogeneic BMT protocols.

        Ages 18 and older and less than age 65.

        Parent of patient (obligate haplotype match) OR HLA 3/6, 4/6, 5/6, or 6/6 match with
        patient.

        Research apheresis available from patient.

        EXCLUSION CRITERIA:

        Pregnancy or lactation.

        HLA type unknown.

        More than one haplotype mismatch with patient.

        History of any immunosuppressive disease.

        History of chronic viral antigenic stimulus.

        Venous access inadequate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. John Barrett, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Datta AR, Barrett AJ, Jiang YZ, Guimar√£es A, Mavroudis DA, van Rhee F, Gordon AA, Madrigal A. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant. 1994 Oct;14(4):517-24.</citation>
    <PMID>7858526</PMID>
  </reference>
  <reference>
    <citation>Mavroudis DA, Jiang YZ, Hensel N, Lewalle P, Couriel D, Kreitman RJ, Pastan I, Barrett AJ. Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant. 1996 May;17(5):793-9.</citation>
    <PMID>8733700</PMID>
  </reference>
  <reference>
    <citation>Mavroudis DA, Dermime S, Molldrem J, Jiang YZ, Raptis A, van Rhee F, Hensel N, Fellowes V, Eliopoulos G, Barrett AJ. Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. Br J Haematol. 1998 Jun;101(3):565-70.</citation>
    <PMID>9633903</PMID>
  </reference>
  <verification_date>March 2, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Volunteer</keyword>
  <keyword>Leukocyte Donors</keyword>
  <keyword>Family Members</keyword>
  <keyword>Leukocyte Collection</keyword>
  <keyword>No Reimbursement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

